Patients with obesity and co-occurring type 2 diabetes may benefit from an antidiabetic medication known to promote weight loss, such as a GLP-1R agonist or GIP/GLP-1R dual agonist [21,26]. This evidence concerns the gene GIP and obesity due to melanocortin 4 receptor deficiency.